Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Cuts Q1 Loss, Prepares to File Ovarian Tumor Test with FDA

NEW YORK (GenomeWeb News) – Vermillion today reported that it had first-quarter revenues of $53,000, compared to $21,000 in the first quarter of 2007, and that it cut its net loss 20 percent year over year.
 
The Fremont, Calif.-based firm is developing molecular diagnostic tests and expects to file its ovarian tumor triage test, called OVA1, with the US Food and Drug Administration within the next couple of months. It also is conducting clinical trials on a test for peripheral arterial disease.
 
Vermillion’s first-quarter product revenues of $5,000 were from sales of thrombotic thrombocytopenic purpura test component materials to the Ohio State University Research Foundation.
 
The firm’s net loss for the quarter was $4.8 million, or $.76 per share, compared to a net loss of $6 million, or $1.54 per share, in the first quarter of 2007.
 
Vermillion’s R&D expenses decreased 5 percent to $1.9 million from $2 million, and its SG&A costs fell 27 percent to $2.7 million from $3.7 million.
 
The company finished the quarter with $8.3 million in cash and cash equivalents.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.